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OBJECTIVES We investigated the antiarrhythmic effects of intrapericardial nitroglycerin (NTG) during
acute myocardial ischemia in the porcine heart.
BACKGROUND Nitroglycerin is a nitric oxide donor that exerts potent effects on the cardiovascular system.
Intrapericardial administration allows investigation of pharmacologic actions on cardiac tissue
in an in vivo system while minimizing the confounding influences of systemic effects.
METHODS In 29 closed-chest pigs, myocardial ischemia was induced by intraluminal balloon occlusion
of the left anterior descending coronary artery. Arrhythmia incidence was monitored during
5-min balloon inflations performed without drug and at 15, 45, 75, and 105 min after NTG
(4,000 g bolus) administered by percutaneous transatrial access into the pericardial space.
Electrocardiograms were monitored for ischemia-induced T-wave alternans (TWA), a
marker of electrical instability. The antiadrenergic potential of NTG was investigated by
examining the drug’s suppression of dobutamine-induced increase in myocardial contractility.
RESULTS Control coronary artery occlusion provoked ventricular fibrillation (VF) in all animals.
Intrapericardial NTG suppressed VF at 45 min in all six pigs (p  0.05) and reduced TWA
across a parallel time course (from 459.1  144.4 V before drug to 42.22  13.96 V at
45 min, p  0.047). The antifibrillatory effect occurred as early as 15 min and persisted for
up to 75 min. Augmentation of maximum of the first time derivative of left ventricular
pressure by dobutamine was blunted by intrapericardial NTG (from 3,999  196 mm Hg/s
before NTG to 3,543  220 mm Hg/s at 15 min, p  0.012).
CONCLUSIONS Intrapericardial NTG exerts a robust antifibrillatory action. Potential mechanisms include
reduction in electrical instability and blunting of adrenergic effects. (J Am Coll Cardiol
2003;41:1831–7) © 2003 by the American College of Cardiology Foundation
Interest is increasing in the direct delivery of agents into the
pericardial space for local treatment of cardiovascular disor-
ders to achieve maximum therapeutic effects and to mini-
mize side effects of systemic administration (1–6). The
intrapericardial approach to local cardiac drug delivery
possesses several intrinsic advantages: 1) delivery into a
low-turnover reservoir, which maximizes contact with tissue
and minimizes loss of agent into circulation; 2) access to
coronary vessels and to the sympathetic and parasympa-
thetic efferent fibers, both of which have significant seg-
ments of epicardial exposure, particularly at the base of the
heart (7,8); 3) perfusion of atrial and ventricular epicardial
tissue to affect ionic currents; 4) reduced exposure to
degradative enzymes, notably those contained in erythro-
cytes; and 5) avoidance of systemic effects. Safe, rapid,
reliable access without thoracotomy to the normal pericar-
dial space has been demonstrated (4,9).
The well-established vascular effects of nitric oxide (NO)
donors are augmented when administered intrapericardially.
The NO donor sodium nitroprusside more effectively pro-
tected against platelet aggregation in stenosed and injured
coronary arteries when administered intrapericardially than
intravenously (3). Intrapericardial nitroglycerin (NTG) pro-
duced persistent coronary vasodilation without systemic
hypotension or reflex elevations in heart rate (HR) (5). The
vasodilatory effect, measured by intravascular ultrasound,
was more pronounced and enduring (3 to 15 min) than an
equal intracoronary dose (200 g bolus). Baek et al. (6)
demonstrated a prolonged vasodilatory effect and positive
remodeling by the NO donor diazeniumdiolated bovine
serum albumin, which has 22-h intrapericardial residence
time, and suggested a clinical application in protecting
against restenosis after angioplasty.
Nitroglycerin is capable of acting at multiple levels
including the coronary vasculature, the cardiac autonomic
nerve supply, and the myocytes themselves, stemming from
its production of the highly permeable gas NO (10–12).
The antiarrhythmic efficacy of intravenous NTG has been
established both experimentally (13–16) and clinically (17–
20). However, the hypotensive effect of systemic adminis-
tration of NTG can decrease antiarrhythmic efficacy (16).
We investigated whether local delivery of nitroglycerin
into the intact pericardial sac to minimize potential systemic
effects could protect against myocardial ischemia-induced
arrhythmias. T-wave alternans (TWA) was quantified to
assess the agent’s effects on ischemia-induced cardiac elec-
trical instability. We also evaluated the agent’s capacity to
protect against dobutamine-induced increase in contractility
as a measure of its potential antiadrenergic activity.
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METHODS
Experimental preparation. This study was conducted ac-
cording to the National Institutes of Health standards and
protocols approved by the institution and conformed to the
“Position of the American Heart Association on Research
Animal Use.” Yorkshire farm pigs (n  29, either gender,
25 to 35 kg) were pre-anesthetized with telazol (4.7 mg/kg,
intramuscularly) and xylazine (2.2 mg/kg, intramuscularly)
and anesthetized with alpha-chloralose (bolus, 100 mg/kg,
intravenously, followed by continuous infusion, 40 mg/kg/h,
intravenously). Arterial PO2, PCO2, and pH were main-
tained in physiologic range with the use of a constant
volume-cycled respirator (Harvard Apparatus, Holliston,
Massachusetts) and supplemental oxygen through endotra-
cheal intubation by tracheostomy. Femoral artery and vein
were cannulated bilaterally with 8F introducer sheaths using
standard protocol. Blood pressure was continuously moni-
tored from a femoral arterial sheath, and intravenous fluids
were administered through a femoral vein. Standard precor-
dial 12-lead electrocardiograms (ECG) were recorded with
a PRUCKA Cardiolab workstation (GE Medical Systems,
Milwaukee, Wisconsin) and analyzed on the MARS work-
station (GE Medical Systems). Unipolar electrograms were
recorded from a monopolar intracoronary lead placed just
beyond the angioplasty balloon positioned downstream of
the first diagonal branch of the left anterior descending
coronary artery (LAD) and from a left ventricular (LV) lead
recorded with reference to Wilson’s central terminal.
Percutaneous transatrial pericardial access. Percutaneous
transatrial pericardial access was performed (4,9). The stiff
end of a standard angioplasty guidewire (0.014-inch Wiz-
dom guidewire, Cordis Corp., Hialeah, Florida) was placed
within the lumen of a soft infusion catheter (0.038-inch
SOS straight tip, open-ended angiographic guidewire, Bard
Interventional Products, Billerica, Massachusetts), advanced
until 1 to 2 mm protruded through the end of the infusion
catheter, and locked with a stopcock in position with
reference to the infusion catheter. This assembly was then
advanced into an 8F multipurpose guide catheter (MP2,
Boston Scientific, Natick, Massachusetts) previously posi-
tioned in the right atrial appendage via a femoral vein under
fluoroscopic guidance. Puncture of the right atrial append-
age was made with the guidewire tip, and the infusion
catheter and guidewire were advanced as a unit into the
pericardial space. Conformation of the infusion catheter to
the exterior curvature of the heart on fluoroscopy verified its
location within the pericardial space. The guidewire was
then removed, and the infusion catheter left in place for
drug delivery. The absence of trauma from the atrial
puncture was verified by1% hematocrit of pericardial fluid
aspirated with the infusion catheter.
Myocardial ischemia induction. Myocardial ischemia was
induced in a closed-chest preparation by intraluminal oc-
clusion of the LAD between the first and second diagonal
branches with standard percutaneous transluminal coronary
angioplasty techniques and equipment (Fig. 1). Under
fluoroscopic guidance, the left main coronary artery was
cannulated with an 8F Judkins right guide catheter (JR4
with side holes, Boston Scientific). A 0.014-inch angio-
plasty guidewire (0.014-inch Wizdom guidewire, Cordis)
was threaded through the LAD past the second diagonal
branch. An angioplasty balloon, 2.5- to 3.5-mm in diameter
and 10- to 20-mm long, was passed over the guidewire to
position the proximal end just beyond the first diagonal
branch and was inflated to occlude the vessel completely, as
verified with angiography. Occurrence of reperfusion ar-
rhythmias was avoided by slow-release of the balloon.
Between occlusions, the balloon was pulled back into the
guide catheter to allow blood flow to resume and to
minimize endothelial trauma. Heparin (5,000 U bolus,
intravenously, followed by 1,000 U/h) was administered to
Abbreviations and Acronyms
cGMP  cyclic guanine monophosphate
ECG  electrocardiogram
HR  heart rate
LAD  left anterior descending coronary artery
LV  left ventricle/ventricular
LV dP/dt max  maximum of the first time derivative of
left ventricular pressure
NO  nitric oxide
NTG  nitroglycerin
SBP  systolic blood pressure
TWA  T-wave alternans
VF  ventricular fibrillation
VPB  ventricular premature beat
Figure 1. Fluoroscopic image of experimental setup for electrophysiology
studies. Infusion catheter (A) in the pericardial space conforms to the
contour of the heart. Angioplasty balloon (B) completely occludes the left
anterior descending coronary artery as demonstrated by dye injection into
the left main coronary artery. Intracoronary guidewire (C) monitors the
intracoronary electrocardiogram (ECG). Electrocatheter (D) positioned in
the left ventricular (LV) ischemic zone records the LV ECG. Pacing
catheter (E) is in the right atrium, positioned via the right internal jugular
vein; 8F multipurpose guide catheter (F) in the right atrial appendage is
used for introducing the pericardial infusion catheter.
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prevent thrombosis. This closed-chest model of intracoro-
nary artery occlusion yielded a high incidence of ventricular
fibrillation (VF) and proved to be reliable, reproducible, and
highly suitable for studying the effects of drugs on ischemia-
induced arrhythmias.
Experimental design. Effects of intrapericardial NTG on
severe ventricular arrhythmias were studied (n  6). Six
5-min LAD coronary artery occlusions were performed 30
min apart (preconditioning, control, 15 min post-drug, 45
min post-drug, 75 min post-drug, and 105 min post-drug).
Nitroglycerin (4,000 g from a 5 mg/ml stock solution
diluted with normal saline) was injected intrapericardially
(10-ml bolus) at 15 min after control occlusion. Precondi-
tioning occlusion results were discarded because of estab-
lished variability. Severity of occlusion-induced arrhythmias
was graded as VF, ventricular tachycardia consisting of 4
consecutive ventricular premature beats (VPB) lasting 15
s, and isolated VPBs. ST-segment deviation was monitored
from precordial lead V3. Saline (10 ml bolus), rather than
NTG, was administered intrapericardially (n  5) to verify
the reproducibility of the experimental model and to provide
control data for the vehicle. Whenever VF ensued, the
balloon was deflated, retracted, and the heart was defibril-
lated.
The effect of intrapericardial NTG (4,000 g bolus) on
TWA was investigated (n  5) during heart-rate pacing at
120 beats/min. Coronary occlusions and intrapericardial
access were performed by the same protocol. Additional
instrumentation included: 1) multipolar, steerable 7F elec-
trocatheter (Bard Electrophysiology, Lowell, Massachu-
setts) inserted into the LV retrogradely from the aorta to
obtain unipolar electrograms from the endocardial surface in
the ischemic zone; 2) LAD coronary guidewire to record
unipolar electrograms from the epicardium in the ischemic
zone; and 3) 6F quadripolar electrocatheter (Bard Electro-
physiology) positioned in the right atrium with the two
most distal poles used for pacing at 120 beats/min. Heart
rate was maintained constant during TWA measurement to
rule out this variable. Arrhythmia grade was not analyzed in
this group due to the ectopy attributable to the LV catheter.
The effects of NTG on intracoronary dobutamine-
induced increases in myocardial contractility were investi-
gated to determine whether or not the agent’s antifibrilla-
tory effect involved post-receptor antiadrenergic action (n 
5). This inotropic sympathomimetic agent was chosen
because of its relatively high selectivity for beta1-adrenergic
receptors, with only mild stimulatory influence on beta2- or
alpha1-vascular receptors (21,22). Three 250-g bolus doses
of dobutamine were injected into the left main coronary
artery at 30-min intervals. The first two injections provided
control information. At 15 min before the third injection,
NTG (4,000 g bolus) was instilled into the pericardial
space. Changes in HR, systolic blood pressure (SBP), and
LV contractility, as measured by the maximum of the first
time derivative of left ventricular pressure (LV dP/dt max),
were recorded via a 7F pigtail catheter (Cordis Corp.) in the
LV.
The hemodynamic effects of NTG administered via the
intravenous or intrapericardial routes were compared (n 
8). Nitroglycerin (4,000 g bolus) was injected in separate
interventions into the pericardial space and into a femoral
vein. Changes in HR, SBP, and LV dP/dt max associated
with the two routes of administration were compared.
TWA and ST-segment analysis. Precordial lead V3
(which recorded the highest TWA values among the surface
leads), intracoronary, and LV intracavitary ECGs were
analyzed at resting baseline and during occlusion for TWA
magnitude, a robust marker of propensity to ischemia-
induced lethal arrhythmias (23–25) by the modified moving
average beat method (25). According to this technique, a
stream of beats was divided into odd and even bins, and the
morphology of the beats in each bin was averaged over a few
beats to create a moving average complex; TWA was
computed every 15 s as the maximum difference in ampli-
tude between the odd-beat and the even-beat average
complexes from the J-point to the end of the T-wave.
ST-segment deviation in the same leads and time points
was calculated as the difference between isoelectric and the
J-point and J-point-plus-60-ms levels for beats averaged for
15 s. ST-segment change was determined as the maximum
difference in ST-segment deviations.
Statistics. Arrhythmia grade and VPB incidence were an-
alyzed using Friedman’s two-way analysis of variance by
ranks with Dunn’s post-hoc test. All other data are reported
as mean  SEM. Values for ST segments, TWA, HR,
SBP, and LV dP/dt max were analyzed by analysis of
variance with correction for repeated measures. A p value of
0.05 was considered statistically significant.
RESULTS
Intrapericardial NTG suppresses ventricular arrhythmias.
Intrapericardial NTG consistently suppressed ischemia-
induced VF. Control occlusions in all six animals resulted in
VF, on average within 4 min after the start of occlusion
(Fig. 2, top panel). At 45 min after intrapericardial NTG,
arrhythmia grade was significantly reduced (p  0.05) with
five of six pigs displaying only VPBs (Fig. 2, bottom panel).
This reduction to VPBs occurred in three of six pigs as early
as 15 min after intrapericardial NTG administration and
generally dissipated by 75 min. Intrapericardial NTG did
not influence the degree of ischemia-induced ST-segment
deviation (lead V3, control: 2.90  0.57 mm; 15 min
post-NTG: 3.18  0.87 mm; 45 min post-NTG: 3.52 
1.11 mm; 75 min post-NTG: 3.12  0.74; 105 min
post-NTG: 2.00  0.98; p  NS). Intrapericardial NTG
did not influence the magnitude of ischemia-induced hypo-
tension and tachycardia, which averaged 10 mm Hg and
10 beats/min, respectively, and did not differ among
occlusions.
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Intrapericardial NTG reduces TWA. Intrapericardial
NTG decreased ischemia-induced TWA magnitude in a
parallel time course with its suppression of ischemia-
induced ventricular arrhythmias (n  5). Nitroglycerin
suppressed TWA during the occlusion at 45 min after NTG
(intracoronary lead, control: 459.1  144.4 V before drug
to 42.22  13.96 V; p  0.047), but TWA recovered by
75 min post-NTG (276.6  233.7 V; p  0.606)
compared with control (Figs. 3 and 4). In the other leads,
the reduction in TWA did not reach significance (LV lead:
control, 112.42  76.38 vs. NTG, 27.18  12.35 V; p 
0.289, and precordial lead V3: control, 162.04  120.1 vs.
NTG, 45.48  30.89 V; p  0.293). In this group,
ST-segment deviations did also not vary among the control
and post-drug coronary occlusions (control, 5.16  1.35
mm; 15 min post-NTG, 4.50  1.04 mm; 45 min post-
NTG, 4.48  0.78 mm; 75 min post-NTG, 4.58  0.53
mm; p  NS).
Intrapericardial NTG attenuates adrenergic stimulation.
Intrapericardial NTG significantly blunted the intracoro-
nary dobutamine-induced augmentation of LV dP/dt max
(n  5). When intracoronary dobutamine was given at
15 min after intrapericardial NTG, an antiadrenergic effect
of intrapericardial NTG was registered in decreased LV
dP/dt max (from 3,999  196 mm Hg/s to 3,543 
220 mm Hg/s, p  0.012), but this effect, although
suggestive, did not achieve statistical significance at 45 min
(3,694 312 mm Hg/s, nNS) and was no longer evident
at 75 min (4,048  708 mm Hg/s, p  NS) after NTG
(Fig. 5). Intrapericardial NTG did not blunt the intra-
coronary dobutamine-induced rise in HR (from 141 
10 beats/min to 137  15 beats/min at 15 min, p  0.62,
to 153  16 beats/min at 45 min, to 152  18 beats/min at
75 min).
HR and hemodynamic response to intravenous versus
intrapericardial NTG administration. Intravenous NTG
(4,000 g bolus) resulted in a transient reduction in systolic
arterial blood pressure and LV contractility (dP/dt max)
(n  6, Fig. 6). By comparison, intrapericardial NTG
(4,000-g bolus) produced a slightly delayed, more moder-
ate, and more persistent decrease in SBP and with a slight
reduction in LV contractility (dP/dt max). In both groups,
Figure 2. Suppression of ischemia-induced arrhythmias with intrapericar-
dial nitroglycerin. (Top) Coronary artery occlusion consistently provoked
severe arrhythmias after intrapericardial saline rather than nitroglycerin
administration (n  5). (Bottom) Arrhythmia severity was reduced 45 min
after intrapericardial nitroglycerin (4,000 g bolus) compared with control
(p  0.05). This reduction in arrhythmia grade appeared as early as 15 min
and lasted up to 75 min in four of six animals. Each line type represents an
individual experiment. VF  ventricular fibrillation; VPB  ventricular
premature beats; VT  ventricular tachycardia (10-s duration).
Figure 3. Ischemia-induced T-wave alternans (TWA) in intracoronary
electrocardiogram tracings in a representative experiment; TWA was not
evident at baseline, before occlusion of the left anterior descending
coronary artery (left). Marked TWA (105.26 V) appeared just before
ventricular fibrillation onset during occlusion without drug (middle) but
was minimized (42.10 V) during the occlusion at 45 min after intraperi-
cardial nitroglycerin (4,000 g bolus) (right).
Figure 4. Intrapericardial nitroglycerin significantly attenuated the magni-
tude of ischemia-induced T-wave alternans (TWA) in the intracoronary
lead at 45 min after delivery (*p  0.05), in parallel with the agent’s effect
on arrhythmias; TWA recovered to pre-drug levels by 75 min after
intrapericardial nitroglycerin.
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there was a transient rise in HR with maximum increase in
the range of 10 beats/min.
DISCUSSION
Intrapericardial NTG potently suppresses ischemia-induced
VF in parallel with TWA, a measure of cardiac electrical
instability. These effects may be mediated through the
agent’s antiadrenergic action, which was implicated by its
blunting the myocardial inotropic response to intracoronary
dobutamine. The present electrophysiologic and antiar-
rhythmic results are consistent with nitroglycerin’s well-
established action as a NO donor.
Antifibrillatory action of NTG. Previous studies per-
formed in a canine model indicated that intravenous NTG
reduced the incidence of ischemia- and reperfusion-induced
VF, increased ventricular electrical stability, reduced isch-
emic injury, and raised the VF threshold of nonischemic
myocardium, especially when hypotensive effects and reflex
sympathetic activation were prevented (13–16). Intravenous
pretreatment with the NO precursor L-arginine protected
against both stunning and reperfusion-induced VF in ca-
nines, probably by lessening endothelial injury (17). Clini-
cally, intravenous NTG reduced the incidence of sustained
repetitive ventricular response during electrophysiologic
testing (18) and the number of ventricular ectopic beats in
patients during acute myocardial infarction (19) and exercise
testing (20).
Whether or not intrapericardial NTG reduces the extent
of ischemic burden and the potential contribution of this
factor to its antiarrhythmic action were unclear. Nitroglyc-
erin’s antiarrhythmic actions occurred in the absence of a
significant reduction in ischemia-induced ST-segment lev-
els in pigs, a species known to have poor collateral circula-
tion (26), which minimizes the effects of vasodilator drugs
on extent of ischemia. However, because ST-segment level
does not provide a direct measure of myocardial blood flow
and ischemia (27,28), definitive demonstration will require
further experiments with assessment of regional myocardial
blood flow and metabolism.
Reduction in TWA. The potent antifibrillatory effect
of intrapericardial NTG was accompanied by a cor-
responding suppression of ischemia-induced TWA. Elec-
trophysiologic mapping studies have determined that this
alternating, beat-to-beat oscillation in T-wave morphology
during myocardial ischemia is indicative of temporal and
spatial unevenness of ventricular repolarization (29–31);
TWA has also been demonstrated to be a measure of
myocardial electrical instability that is correlated with
the likelihood of life-threatening arrhythmias in diverse
clinical conditions (32,33) and experimental settings (34).
Intrapericardial NTG’s suppression of TWA was maxi-
mum at 45 min post-drug, the period when NTG exerted
its peak antiarrhythmic action. This effect was marked in
Figure 5. Effect of intrapericardial nitroglycerin on the rise in contractility
in response to intracoronary bolus injections of dobutamine. At 15 min
after intrapericardial nitroglycerin, the rise in contractility induced by
intracoronary dobutamine was significantly blunted (*p  0.05). Thereaf-
ter, nitroglycerin’s effect did not achieve statistical significance. LV dP/dt
max  maximum of the first time derivative of left ventricular pressure.
Figure 6. Heart rate and hemodynamic response to intravenous (IV) (open
circles) as compared with intrapericardial (IPC) (filled circles) nitroglyc-
erin administration. The period of IV monitoring was 40 min, correspond-
ing to a time when the effect of IV nitroglycerin would be expected to be
completely dissipated, and, in fact, the values had all returned to baseline
at that point. The effects of IPC nitroglycerin were monitored for 75 min,
the anticipated period of action and potential antiarrhythmic effects. *p 
difference from pre-drug baseline, 0.05. The results were obtained in a
total of eight animals, four of which received both IV and IPC nitroglyc-
erin, and the remaining four received the drug through either the IV or
IPC route. Randomizing the protocol was intended to reduce possible
sequence-related effects.
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the intracoronary lead, which monitors the epicardial sur-
face.
Attenuation of adrenergic influences. Fei et al. (35)
demonstrated a pre-receptor, antiadrenergic effect of the
NO precursor L-arginine using an open-chest canine model
with a pericardial cradle. They reported that norepinephrine
overflow from the coronary sinus induced by sympathetic
nerve stimulation was diminished after bathing with
L-arginine and postulated this mechanism for the agent’s
reduction of ischemia-induced ventricular arrhythmias. Our
results demonstrate post-receptor antiadrenergic action, as
intrapericardial NTG attenuated the inotropic response to
intracoronary infusion of dobutamine, a sympathomimetic
agent. This observation is consistent with previous findings
indicating that NO significantly influences the myocardial
contractile response to beta-adrenergic stimulation by do-
butamine in normal dogs (36) and in humans with either
LV dysfunction (37) or idiopathic dilated cardiomyopathy
(38). The postulated basis for NO’s negative inotropic
responses during beta-adrenergic stimulation involves in-
creased intracellular cyclic guanine monophosphate
(cGMP), which inhibits the beta-adrenergic-stimulated
increase in the L-type calcium channel current and reduces
calcium affinity of the contractile apparatus (10) and has
been shown to reduce cyclic adenosine 3:5-cyclic phos-
phate levels after direct beta-adrenergic stimulation (39), as
well as the numerous downstream countervailing effects of
cGMP in sympathetically stimulated myocardium. Nitro-
glycerin’s suppression of TWA may also reflect blunting of
adrenergic influences, which affect TWA magnitude (40).
The basis for intrapericardial NTG’s inability to blunt the
HR increase provoked by intracoronary dobutamine is not
known. A possible explanation is that the effects of NO on
the sinus node pacemaker current (If) are quite variable and
can include a stimulatory as well as an inhibitory response
(41,42).
The functional half-life of intrapericardial NTG can be
inferred from these data as 15 to 45 min, whereas intrave-
nous NTG has a half-life of 3 to 5 min (43), with
cardiovascular effects lasting 10 to 15 min. This prolonga-
tion in effect is most likely attributable to the absence of
erythrocytes and their degradative enzymes from pericardial
fluid, which had a hematocrit of 1%. The slow, gradual
onset of the hemodynamic effects of intrapericardial NTG
confirms the minimum leakage of nitroglycerin from the
pericardial space.
Implications. Intrapericardial administration of NTG ex-
erts a potent antifibrillatory effect. This action probably
relates to the formation of NO, which is capable of blocking
adrenergic profibrillatory influences and improving calcium
handling during severe myocardial ischemia. From a
broader perspective, these results underscore the potential
for sustained action by cardioactive agents when delivered
intrapericardially and highlight the potential utility of the
NO pathway. Percutaneous delivery of these substances into
the pericardial space could prove valuable both in elucidat-
ing fundamental modes of pharmacologic action and in
leading to new therapeutic approaches to contain triggers of
life-threatening arrhythmias.
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